Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Garry A. Neil M.D. | President, CEO & Director | 1.03M | -- | 1954 |
| Mr. Christopher Ryan Sullivan CPA | CFO & Head of Investor relations | 629.4k | -- | 1984 |
| Dr. Mittie Doyle FACR, M.D. | Chief Medical Officer | 678.12k | -- | 1965 |
| Dr. Solomon H. Snyder M.D. | Founder and Chairman of Scientific Advisory Board | -- | -- | 1939 |
| Dr. Barbara S. Slusher Ph.D. | Founder and Member of Scientific Advisory Board | -- | -- | 1965 |
| Mr. Paul C. Varki J.D., M.P.H | Chief Legal Officer | -- | -- | 1973 |
| Dr. Lisa Hegg Ph.D. | Senior Vice President of Program Management, Corporate Infrastructure & Clinical Operations | -- | -- | -- |
| Ms. Colleen Matkowski | Senior Vice President of Global Regulatory Affairs & Quality Assurance | -- | -- | -- |
| Dr. Dino C. Miano Ph.D. | Senior Vice President of CMC & Technical Operations | -- | -- | -- |
| Ms. Jennifer Riley | Chief Strategy Officer | -- | -- | 1975 |
Avalo Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 23
Description
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
Corporate Governance
Upcoming Events
May 12, 2025 at 12:30 PM UTC - May 16, 2025 at 12:30 PM UTC
Avalo Therapeutics, Inc. Earnings Date